RGEN Stock Analysis: Repligen | NASDAQ

Bioprocessing Systems, Chromatography Columns, Filtration Devices, Analytical Instruments

Total Rating 57

Safety 90

Buy Signal 0.48

Medical Instruments & Supplies
Industry Rotation: -1.6

Market Cap: 11.0B
Avg Turnover: 188M

Risk 3d forecast

Volatility55.7%

VaR 5^th Pctl9.01%

VaR vs Median-1.84%

Reward TTM

Sharpe Ratio0.67

Rel. Str. IBD88.1

Rel. Str. Peer Group46.6

Character TTM

Beta1.018

Beta Downside0.484

Hurst Exponent0.466

Drawdowns 3y

Max DD50.64%

CAGR/Max DD0.14

CAGR/Mean DD0.26

EPS (Earnings per Share)

EPS CAGR: 5.61%
EPS Trend: 18.2%

Last SUE: 0.66
Qual. Beats: 0

Revenue

Rev. CAGR: 9.22%
Rev. Trend: 86.8%

Last SUE: 0.90
Qual. Beats: 1

Warnings

P/E Ratio 262.3

Tailwinds

Avwap Ph Week

Seasonality 11.7 years of data

Jan -3.8% 5

Feb -0.7% 17

Mar -4.2% 23

Apr +2.4% 5

May +1.9% 8

Jun +3.8% 18

Jul +5.1% 29

Aug +4.5% 37

Sep -5.4% 38

Oct -4.5% 44

Nov +8.3% 43

Dec -4.6% 39

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: RGEN Repligen

Repligen Corporation (NASDAQ: RGEN) is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the manufacture of biological drugs. Headquartered in Waltham, Massachusetts and founded in 1981, the company sells its products globally across North America, Europe, and the Asia Pacific to biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations (CMOs).

Its product portfolio spans consumables and instruments across several bioprocessing categories, including hollow fiber filtration consumables, the KRM chromatography system, Protein A affinity ligands and resins used in monoclonal antibody purification, ELISA test kits, OPUS pre-packed chromatography columns, and filtration systems such as the XCell ATF Cell Retention System, TangenX flat sheet cassettes, and KrosFlo tangential flow filtration systems. Repligen also offers a range of process analytics tools under the PATsmart family for real-time monitoring of critical bioprocess parameters, along with slope spectroscopy devices branded SoloVPE and FlowVPE.

The company markets its products under brands including OPUS, XCell, XCell ATF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, RPM, XO, Metenova MixOne, and AVIPure. Repligen maintains a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands, supporting its position in the affinity chromatography segment of the bioprocessing supply chain.

Headlines to Watch Out For

Bioprocessing revenue growth driven by gene therapy demand
Protein A resin margins face competition from Cytiva and Sartorius
Capital allocation shifts toward M&A and capacity expansion

Piotroski VR-10 (Strict) 3.0

Net Income: 41.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.10 > 1.0
NWC/Revenue: 136.0% < 20% (prev 138.6%; Δ -2.54% < -1%)
CFO/TA 0.05 > 3% & CFO 134.9m > Net Income 41.5m
Net Debt (20.4m) to EBITDA (121.8m): 0.17 < 3
Current Ratio: 9.05 > 1.5 & < 3
Outstanding Shares: last quarter (56.7m) vs 12m ago 0.27% < -2%
Gross Margin: 51.05% > 18% (prev 44.25%; Δ 6.80% > 0.5%)
Asset Turnover: 26.83% > 50% (prev 23.23%; Δ 3.61% > 0%)
Interest Coverage Ratio: 1.37 > 6 (EBIT TTM 77.5m / Interest Expense TTM 56.6m)

Altman Z'' 5.72

A: 0.36 (Total Current Assets 1.20b - Total Current Liabilities 132.7m) / Total Assets 2.95b
B: 0.16 (Retained Earnings 469.6m / Total Assets 2.95b)
C: 0.03 (EBIT TTM 77.5m / Avg Total Assets 2.93b)
D: 2.52 (Book Value of Equity 2.11b / Total Liabilities 838.1m)
Altman-Z'' = 5.72 = AAA

Beneish M -3.18

DSRI: 0.86 (Receivables 157.7m/157.0m, Revenue 785.1m/674.0m)
GMI: 0.87 (GM 44.25% / 51.05%)
AQI: 0.95 (AQ_t 0.50 / AQ_t-1 0.53)
SGI: 1.16 (Revenue 785.1m / 674.0m)
TATA: -0.03 (NI 41.5m - CFO 134.9m) / TA 2.95b)
Beneish M = -3.18 (Cap -4..+1) = AA

What is the price of RGEN shares?

As of October 06, 2026, the stock is trading at USD 189.50 with a total of 1,423,517 shares traded. Over the past week, the price has changed by -2.36%, over one month by +12.44%, over three months by +33.96% and over the past year by +26.25%.

Current recommended Stop Loss: 180.10 (which is 5% or 1.2 ATR below the current price).

Is RGEN a buy, sell or hold?

Repligen has received a consensus analysts rating of 4.26. Therefore, it is recommended to buy RGEN.

StrongBuy: 10
Buy: 4
Hold: 5
Sell: 0
StrongSell: 0

What are the forecasts/targets for the RGEN price?

Analysts Target Price	189.5	-0%

Repligen (RGEN) - Fundamental Data Overview as of 30 September 2026

Market Cap USD = 11.0b (11.0b USD * 1.0 USD.USD)
P/E Trailing = 262.2838
P/E Forward = 67.1141
P/S = 13.9518
P/B = 4.9303
P/EG = 1.8399
Revenue TTM = 785.1m USD
EBIT TTM = 77.5m USD
EBITDA TTM = 121.8m USD
Long Term Debt = 551.0m USD (from longTermDebt, last quarter)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 830.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 139.9m
Net Debt = 20.4m USD (calculated: Debt 830.8m - CCE 810.4m)
Enterprise Value = 11.0b USD (11.0b + Debt 830.8m - CCE 810.4m)
Interest Coverage Ratio = 1.37 (Ebit TTM 77.5m / Interest Expense TTM 56.6m)
EV/FCF = 99.06x (Enterprise Value 11.0b / FCF TTM 110.8m)
FCF Yield = 1.01% (FCF TTM 110.8m / Enterprise Value 11.0b)
FCF Margin = 14.11% (FCF TTM 110.8m / Revenue TTM 785.1m)
Net Margin = 5.29% (Net Income TTM 41.5m / Revenue TTM 785.1m)
Gross Margin = 51.05% ((Revenue TTM 785.1m - Cost of Revenue TTM 384.3m) / Revenue TTM)
Gross Margin QoQ = 53.08% (prev 50.70%)
Tobins Q-Ratio = 3.72 (Enterprise Value 11.0b / Total Assets 2.95b)
Interest Expense / Debt = 6.81% (Interest Expense 56.6m / Debt 830.8m)
Taxrate = 20.35% (10.6m / 52.1m)
NOPAT = 61.7m (EBIT 77.5m * (1 - 20.35%))
Current Ratio = 9.05 (Total Current Assets 1.20b / Total Current Liabilities 132.7m)
Debt / Equity = 0.39 (Debt 830.8m / totalStockholderEquity, last quarter 2.11b)
Debt / EBITDA = 0.17 (Net Debt 20.4m / EBITDA 121.8m)
Debt / FCF = 0.18 (Net Debt 20.4m / FCF TTM 110.8m)
Total Stockholder Equity = 2.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.42% (Net Income 41.5m / Total Assets 2.95b)
RoE = 1.98% (Net Income TTM 41.5m / Total Stockholder Equity 2.10b)
RoCE = 2.92% (EBIT 77.5m / Capital Employed (Equity 2.10b + L.T.Debt 551.0m))
RoIC = 2.21% (NOPAT 61.7m / Invested Capital 2.80b)
WACC = 9.27% (E(11.0b)/V(11.8b) * Re(9.56%) + D(830.8m)/V(11.8b) * Rd(6.81%) * (1-Tc(0.20)))
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 17.01 | Cagr: 0.10%
[DCF] Terminal Value 72.92% ; FCFF base≈108.8m ; Y1≈113.4m ; Y5≈129.4m
[DCF] Fair Price = 30.21 (EV 1.73b - Net Debt 20.4m = Equity 1.71b / Shares 56.4m; r=9.27% [WACC]; 5y FCF grow 4.56% → 2.50% )
EPS Correlation: 18.24 | EPS CAGR: 5.61% | SUE: 0.66 | # QB: 0
Revenue Correlation: 86.77 | Revenue CAGR: 9.22% | SUE: 0.90 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.46 | Chg30d=-0.09% | Revisions=+6% | Analysts=18
EPS current Year (2026-12-31): EPS=2.06 | Chg30d=+0.00% | Revisions=+87% | GrowthEPS=+20.7% | GrowthRev=+12.0%
EPS next Year (2027-12-31): EPS=2.65 | Chg30d=+0.40% | Revisions=+50% | GrowthEPS=+28.4% | GrowthRev=+17.8%
[Analyst] Revisions Ratio: +58% (up=42, down=10)